$212 Million is the total value of MPM ASSET MANAGEMENT LLC's 8 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
RDUS | Radius Health, Inc. | $147,842,000 | -29.7% | 3,887,502 | 0.0% | 69.78% | +1.3% | |
EPZM | EpiZyme, Inc. | $20,929,000 | +23.0% | 1,729,674 | 0.0% | 9.88% | +77.2% | |
SNDX | Syndax Pharmaceuticals, Inc. | $15,550,000 | -52.7% | 2,168,691 | 0.0% | 7.34% | -31.8% | |
CHMA | Chiasma, Inc. | $11,186,000 | -33.7% | 5,736,296 | 0.0% | 5.28% | -4.4% | |
ELGX | Endologix, Inc. | $6,415,000 | -55.3% | 1,121,447 | 0.0% | 3.03% | -35.6% | |
CNAT | Conatus Pharmaceuticals, Inc. | $6,282,000 | +163.5% | 1,192,080 | 0.0% | 2.96% | +279.6% | |
PRTO | Proteon Therapeutics, Inc. | $1,868,000 | -79.6% | 983,381 | 0.0% | 0.88% | -70.6% | |
PETX | Aratana Therapeutics Inc. | $1,795,000 | -23.3% | 250,000 | 0.0% | 0.85% | +10.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-07
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR/A | 2023-09-07 |
13F-HR | 2023-08-14 |
4 | 2023-06-05 |
4 | 2023-05-24 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-11 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.